Related Experiment Video
Updated: May 14, 2026
Generation, Purification, and Characterization of Cell-invasive DISC1 Protein Species
Published on: August 30, 2012
A Degron Decoy System Co-opts Pathological Seeding to Enable Clearance of Multimeric α-Synuclein
Gillian E Gadbois1,2, Alexander P Plonski1,2, Galia T Debolouchina1,2
1Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA 92093.
Abstract:
Pathological seeding of protein misfolding is a hallmark of proteinopathies. However therapeutic strategies to clear these aggregates are lacking, impairing both study of their biological importance in disease etiology and progression as well as development of therapeutics. This is due in part to the need to selectively clear oligomerized proteins whilst leaving functional monomers intact, as well as the challenge of developing molecules that act on the full complement of 'misfolds' the protein can adopt throughout the course of disease. In this work, we describe a dopant system consisting of an engineered alpha-synuclein protein construct that rapidly co-aggregates into existing WT alpha-synuclein oligomers, enabling rapid degradation of the entire assembly in the presence of a small molecule trigger. This work provides proof-of-principle for an approach that transforms pathological seeding from a disease-driver into a therapeutic vulnerability, and is potentially applicable to any proteinopathy without requiring a small molecule binder of the pathologic species.
Insights
Researchers developed a novel dopant system using engineered alpha-synuclein to target and degrade protein aggregates in proteinopathies. This innovative approach turns pathological seeding into a therapeutic vulnerability for potential treatment of various neurodegenerative diseases.
Area of Science:
- Neuroscience
- Biochemistry
- Molecular Biology
Background:
- Protein misfolding and aggregation are central to proteinopathies.
- Current therapeutic strategies for clearing protein aggregates are limited.
- Selective clearance of toxic oligomers while preserving functional monomers is challenging.
Purpose of the Study:
- To develop a novel therapeutic strategy for proteinopathies.
- To engineer a system that targets and degrades pathological protein aggregates.
- To transform protein aggregation from a disease driver into a therapeutic vulnerability.
Main Methods:
- Engineered an alpha-synuclein protein construct as a dopant system.
- Demonstrated rapid co-aggregation of the engineered construct with wild-type (WT) alpha-synuclein oligomers.
- Utilized a small molecule trigger for degradation of the entire protein assembly.
Main Results:
- The dopant system effectively co-aggregates with existing WT alpha-synuclein oligomers.
- Rapid degradation of the aggregated protein assembly was achieved upon small molecule activation.
- Proof-of-concept for a new therapeutic approach targeting proteinopathies was established.
Conclusions:
- The engineered dopant system offers a potential therapeutic strategy for proteinopathies.
- This approach leverages pathological seeding as a vulnerability for aggregate clearance.
- The system is potentially applicable to diverse proteinopathies without specific small molecule binders for each pathologic species.
